Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...

Key products such as Entresto, Cosentyx, Kesimpta, and Kisqali showed significant sales growth, contributing to the company's robust performance. Novartis AG (NYSE:NVS) has a promising pipeline ...

Novartis has performed well in the previous ... Top drugs like Entresto (cardiovascular) and Cosentyx (psoriasis, spondylitis and arthritis) performed well in 2024. Cosentyx sales are being ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

Key products such as Entresto, Cosentyx, Kesimpta, and Kisqali showed significant sales growth, contributing to the company's robust performance. Novartis AG (NYSE:NVS) has a promising pipeline with ...

Novartis operates as a single global operating segment. It now concentrates on four core therapeutic areas — cardiovascular, renal, metabolic, immunology, neuroscience and oncology. Top drugs like ...